Skip to content

NLR and PRL in Neurocognitive Disorders

The Effect of NLR and PLR on Perioperative Neurocognitive Disorders in Patients Undergoing Elective Non-cardiac Surgery Under General Anesthesia.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04736290
Enrollment
288
Registered
2021-02-03
Start date
2015-12-01
Completion date
2021-12-30
Last updated
2021-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurocognitive Disorders, Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio

Keywords

Neurocognitive disorders, Neutrophil-Lymphocyte ratio, Platelet-Lymphocyte ratio

Brief summary

Preliminary evidence suggest a possible relationship between Neutrophil-Lymphocyte Ratio (NLR) and Platelet-Lymphocyte Ratio (PLR) and perioperative neurocognitive disorders (NCD). We are going to investigate whether the values of NLR and PLR in patients undergoing elective non-cardiac surgery under general anesthesia, are related with increased risk of perioperative NCD.

Detailed description

It is estimated that approximately 10% of elderly undergoing surgery will develop cognitive changes perioperatively, while in some reports the incidence rises up to 80%. Despite the reported high prevalence of perioperative neurocognitive disorders (NCD), their exact etiology is still largely unknown. Preliminary evidence suggest a possible relationship between Neutrophil-Lymphocyte Ratio (NLR) and Platelet-Lymphocyte Ratio (PLR) and perioperative neurocognitive disorders (NCD). We are going to investigate whether the values of NLR and PLR in patients undergoing elective non-cardiac surgery under general anesthesia, are related with increased risk of perioperative NCD.

Interventions

OTHERNLR

Calculation of NLR

OTHERPLR

Calculation of PLR

Sponsors

University Hospital, Ioannina
CollaboratorOTHER
Larissa University Hospital
CollaboratorOTHER
University of Thessaly
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
45 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* 45 - 80 years * American Society of Anesthesiologists physical status I to III * elective general, urological, gynecological and orthopedic surgery under general anesthesia * native speakers of the Greek language

Exclusion criteria

* refused to participate or sign the informed consent form * had undergone surgery or anesthesia within the last 30 days * had any prior or current history involving an affliction of the central nervous system * were diagnosed with severe cognitive decline based on the 16 - item Informant Questionnaire on Cognitive Decline (IQCODE - 16) * suffered from severe hearing or visual impairment * any psychiatric disorder * had a score \>5 in the Geriatric Depression Scale (GDS - 15) * or a score in females \< 4 males \< 2 in the Lawton - Brody Instrumental Activities of Daily Living Scale (I.A.D.L.) * reported alcohol consumption \> 35 units/week * drug dependence * had undergone previous neuropsychological testing * Diabetes Mellitus type II with \> 10 years of diagnosis * Diabetes Mellitus type I * Hemoglobin A1c (HbA1c) \> 7.5% * suffered from hemodynamical instability (\> 20% alterations of blood pressure perioperatively) * or desaturation (one or more events of SpO2 \< 80% for more than 2 minutes) peri-operatively * or blood loss of more than one unit

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Postoperative neurocognitive disorders assessed with CAM1st postoperative dayIncidence of POD assessed with CAM
Incidence of Postoperative neurocognitive disorders assessed with IQCODE-1610th postoperative dayIncidence of POCD assessed with IQCODE-16

Countries

Greece

Contacts

Primary ContactMaria Ntalouka, MD, PhD
maria.ntalouka@icloud.com+306973688099
Backup ContactMetaxia Bareka, MD, PhD
barekametaxia@hotmail.com+306947845083

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026